Sign up to save your podcasts
Or
Share Why WeightWatchers Wants in on Drugs Like Ozempic
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Why WeightWatchers Wants in on Drugs Like Ozempic
WeightWatchers is buying digital health company Sequence to capitalize on the hot market for diabetes and weight loss drugs including Ozempic and Wegovy. WSJ's Andrea Petersen explains what this could mean for the wellness industry.
Further Reading:
-WeightWatchers Moves Into the Ozempic Market With Telehealth Deal
-How a Diabetes Drug Became the Talk of Hollywood, Tech and the Hamptons
-Health Startups Offer Diabetes Drugs Like Ozempic for Weight Loss With Little Oversight
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By The Wall Street Journal & Spotify Studios
4.2
55465,546 ratings
WeightWatchers is buying digital health company Sequence to capitalize on the hot market for diabetes and weight loss drugs including Ozempic and Wegovy. WSJ's Andrea Petersen explains what this could mean for the wellness industry.
Further Reading:
-WeightWatchers Moves Into the Ozempic Market With Telehealth Deal
-How a Diabetes Drug Became the Talk of Hollywood, Tech and the Hamptons
-Health Startups Offer Diabetes Drugs Like Ozempic for Weight Loss With Little Oversight
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like The Journal.
View all
Planet Money
30,655 Listeners
WSJ Opinion: Potomac Watch
2,839 Listeners
WSJ Your Money Briefing
1,718 Listeners
WSJ What’s News
4,363 Listeners
WSJ Tech News Briefing
1,642 Listeners
The Daily
112,683 Listeners
WSJ Minute Briefing
670 Listeners
Up First from NPR
56,469 Listeners
Bold Names
1,450 Listeners
The Indicator from Planet Money
9,514 Listeners
Today, Explained
10,269 Listeners
Post Reports
5,465 Listeners
Barron's Streetwise
1,553 Listeners
Bad Bets
1,322 Listeners
WSJ Opinion: Free Expression
606 Listeners
As We Work
151 Listeners
WSJ's Take On the Week
146 Listeners